Abstract Library

#3030 Targeting CXCR4 and Thioredoxin Reductase in Theranostics of Atypical Carcinoid and Neuroendocrine Carcinoma

Introduction: Atypical carcinoid and small cell lung cancer (SCLC) are currently incurable. There is thus a critical need for new diagnostic and therapeutic strategies for lung neuroendocrine neoplasms (LNEN). Chemokine receptor 4 (CXCR4), a G protein coupled receptor and theranostic target, plays a crucial role in metastases of LNEN. We hypothesize combination of thioredoxin reductase (TR) inhibitor represents a metabolic strategy to enhance cytotoxicity in peptide-receptor radionuclide therapy (PRRT) of LNEN.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Liu D

Authors: Liu D, Fath M, Robles Planells C, Balk E, Bellizzi A,

Keywords: CXCR4, thioredoxin reductase inhibitor, theranostics, atypical carcinoid, small cell lung cancer,

#2961 Our Experience Using a New Scoring System to Detect Disease Recurrence after Curative Surgical Resection of Well-Differentiated Pancreatic Neuroendocrine Tumors

Introduction: For patients with nonfunctioning pNET  ≥20 mm in size without distant metastasis, complete surgical resection is recommended as the primary curative strategy. Effective follow‐up programs are designed to detect recurrence at an early stage, given that treatment of limited disease has the most favorable outcome. However, data on post‐curative surgical recurrence remains limited, making it challenging to determine the best follow‐up strategy and to detect the best treatment options as an adjuvant therapy for selected patients.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Mastrangelo L

Authors: Mastrangelo L, Cipressi C, Masetti M, Zanello M, Romboli A,

Keywords: nomogram, pancreatic neuroendocrine tumor, recurrence,

#2957 New Evidence of Emerging Nodal Metastasis in Staging System after Surgical pNET Resection as Predictive Factor for Recurrence. Result from Monocentric Retrospective Series

Introduction: New evidence is emerging of the role of pNETs lymphatic metastasis in terms of Oncological Outcomes. A specific staging classification is not actually available.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Mastrangelo l

Authors: Mastrangelo L, Romboli A, Masetti M, Zanello M, Cipressi C,

Keywords: lymph node status, neuroendocrine tumor, pancreas, prognosis, surgery,

#2928 Survey of Challenges in Access to Diagnostics and Treatment for Neuroendocrine Tumour (NET) Patients (SCAN) – Assessment of Early Diagnosis

Introduction: SCAN measured global readiness to provide diagnostics and treatments for NET patients in terms of awareness, availability, quality and affordability.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Van Genechten D

Authors: Van Genechten D, McDonnell M, Rodien-Louw C, Dureja S, Leyden S,

Keywords: Neuroendocrine Tumours, Survey, Earlier diagnosis,

#2740 Long-Term Complete Response in Metastatic Poorly-Differentiated Neuroendocrine Rectal Carcinoma with Multimodal Approach. A Case Report

Introduction: Rectal neuroendocrine carcinomas (NEC) are extremely rare and account for less than 1% of colorectal malignancies.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Della Torre S

Authors: Lombardi P, Grandi S, Marinelli M, Manara M, Della Torre S,

Keywords: rectal nec, net, chemotherapy, metastatic disease,